Dinesh Dua

Dinesh Dua, Director of Nectar Lifesciences Dinesh Dua said the company stands to gain from pharmacies destocking due to demonetisation. He expects a good Q4 show as chemists will restock supplies.

Will maintain current EBITDA levels: Nectar Lifesciences

In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and his outlook for the company.

Expect double-digit growth in FY15: Nectar Life

In an interview to CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences details the Q1 performance of the company and what he expects in the future.

API facility to boost revenue by 5-10%: Nectar Lifesciences

Nectar Lifesciences has received European approval for its Cephalosporin APIs manufacturing facility at Derabassi in Punjab. Dinesh Dua, chief executive director at Nectar Lifesciences, in an interview to CNBC-TV18, said the API manufacturing facility is likely to boost the company’s revenues by 5-10%.

Regulated markets to fetch Rs 250-300cr in 2 years: Nectar

Dinesh Dua, CEO, Nectar Lifesciences in an interview with CNBC-TV18 spoke about the latest happenings in the company and the road ahead.

USFDA nod will open up lucrative market for us: Nectar Lifesciences

In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said, "It’s going to happen at April. As soon as the approval is through we will be able to supply our API to lots of customers."

Nectar Lifesciences targets Rs 1300cr revenues in FY12

In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said,"We are looking at about close to Rs 1,300 plus crore topline for the next year."

Nectar Lifesciences eyes Rs 1300cr topline in FY12

In an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and the road ahead.